Navigation Links
Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
Date:10/1/2007

Study Data Show Patients with Moderate to Severe Psoriasis Who Responded to Anti-IL-12/23 ABT-874 after 12 Weeks of Treatment, Maintained Response at

24 Weeks

BUENOS AIRES, Argentina, Oct. 1 /PRNewswire-FirstCall/ -- Results from an extension to a Phase II study evaluating the effectiveness of Abbott's (NYSE: ABT) investigational anti-IL-12/23 antibody ABT-874 showed that a majority of patients who initially responded to treatment maintained a high level of response following discontinuation of therapy. In the study, patients who achieved 75 percent improvement in psoriasis signs and symptoms (PASI 75) at 12 weeks stopped receiving ABT-874. At 24 weeks, more than two- thirds of these patients maintained at least 50 percent improvement (PASI 50). The Phase II study, conducted in patients with moderate to severe psoriasis, will be presented at the World Congress of Dermatology in Buenos Aires.

Phase II results presented earlier this year at the Society for Investigative Dermatology (SID) Meeting showed ABT-874 reduced psoriasis symptoms significantly in the majority of patients treated. At 12 weeks, at least 90 percent of patients with moderate to severe psoriasis achieved 75 percent improvement in psoriasis signs and symptoms in all but the lowest dosing groups receiving ABT-874, versus 3 percent of patients receiving placebo. Also, more than half of patients achieved 90 percent improvement, in the same four of five ABT-874 dosing groups, versus 0 percent of those receiving placebo.

"ABT-874 represents a novel approach to treating psoriasis, targeting a part of the inflammatory response that is not addressed by any therapy available today," said Alan Menter, MD, Chair,
'/>"/>

SOURCE Abbott
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
5. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
6. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
7. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
8. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
9. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
10. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
11. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients ... to a recent online survey* sponsored by Mission Pharmacal ... the National Osteoporosis Foundation online support community, revealed that ... medication that comes in a form other than a ...
(Date:1/15/2014)... Jan. 15, 2014 AARP Foundation today announced it has ... suffering from the severe cold weather that has gripped much ... helping those in need; so to support these emergency relief ... to $250,000, which could mean up to $500,000 in aid. ...
(Date:1/15/2014)... Calif. , Jan. 15, 2014 Massachusetts ... (NASDAQ: AMGN ) announced today that ... discover and validate new therapeutic targets and develop ... chronic disorder that affects millions worldwide. The MGH-Broad-Amgen ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... CVS Caremark Corporation (NYSE: CVS ) today ... dividend of $0.125 (12.5 cents) per share on the Common ... of record on July 22, 2011. (Logo: ... CVS Caremark is the largest pharmacy health care provider ...
... Reportlinker.com announces that a new market ... Growth Hormone Deficiency Global ... http://www.reportlinker.com/p0567405/Growth-Hormone-Deficiency-Global-Clinical-Trials-Review-Q2-2011.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development Growth ... 2011 Summary ...
Cached Medicine Technology:Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 2Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 3Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 4Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 5Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 6Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 7Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 8Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 9
(Date:4/17/2014)... Colic affects about one in five infants in the ... during the first several months after birth. Research into ... promise; however, the April 1, 2014 issue of the ... on a study, "Probiotics and Infant Colic," concluding that ... for infant colic did not reduce crying or ...
(Date:4/17/2014)... University School of Medicine (BUSM) have discovered that ... an experimental model. The findings, reported in the ... , may lead to more effective treatments for ... of the leading causes of illness and death ... impact by limiting the productivity of workers and ...
(Date:4/17/2014)... An international team led by researchers at UC Davis ... plays a key role in cell division, also boosts ... the first time the complex has been shown to ... B1/Cdk1 an excellent target to control cellular energy production, ... was published online today in the journal Developmental ...
(Date:4/17/2014)... An international research team led by Cesar A. Arias, ... Center at Houston (UTHealth) has identified a new superbug ... The report appeared in the April 17 issue of ... The new superbug is part of a class of ... or MRSA, which is a major cause of hospital ...
(Date:4/17/2014)... days to find a colored ribbon representing a disease. A ... what color ribbon does one think of with lung cancer?, ... many suffering from the disease, black may be the only ... of lung cancer patients, primarily smokers between the ages of ... the stigma often felt by these patients, the emotional toll ...
Breaking Medicine News(10 mins):Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... expert says, , WEDNESDAY, July 22 (HealthDay News) -- When ... kind of snack that matters, but who eats it. , ... women, the healthy-weight women wanted less of the treat over ... non-obese women respond to high-energy, high-density snacks in different ways," ...
... , , IRVINE, Calif., July ... Pulse CO-Oximetry and Measure-Through Motion and Low-Perfusion pulse oximetry, today announced it ... 4, 2009 after the market closes on Tuesday, August 4, 2009. , ... results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will ...
... , , , ... July 22 Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. ... cooperative group-sponsored randomized Phase 2 trial in advanced metastatic breast ... evaluated Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic, ...
... , , BATON ROUGE, ... manage cleanup efforts in hurricane-ravaged areas. Assisting in the diagnosis and ... which one is practically required to live at the gym and work ... careers are both varied and interesting. . .many of them coming with ...
... ... HSA Bank, two innovators in health savings accounts, have announced a new marketing ... easy access to HSA Bank through the My HSA Rewards website to learn ... HSA Bank customers will be given the opportunity to enroll in My HSA ...
... The Centers ... much as 4.5 percent by the year 2010. The additional costs could be passed along ... ... likely increase costs to seniors for their Medicare Advantage health insurance plans, in April the ...
Cached Medicine News:Health News:Eating Habits in the Obese May Echo Drug Addicts' Patterns 2Health News:Eating Habits in the Obese May Echo Drug Addicts' Patterns 3Health News:Masimo to Report Second Quarter 2009 Financial Results on August 4, 2009 2Health News:Masimo to Report Second Quarter 2009 Financial Results on August 4, 2009 3Health News:Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer 2Health News:Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer 3Health News:Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer 4Health News:Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer 5Health News:Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer 6Health News:MedVance Institute To Offer New High-Demand Courses 2Health News:MedVance Institute To Offer New High-Demand Courses 3Health News:HSA Bank and My HSA Rewards Offer a New Way for HSA Bank Customers to Help Pay for Their Health Care 2Health News:HSA Bank and My HSA Rewards Offer a New Way for HSA Bank Customers to Help Pay for Their Health Care 3Health News:Medicare Agency Announces Decreased Payments to Medicare Advantage Insurers in 2010, Says MedicareSupplementPlans.com 2
... The SurgiGraphic 6000 lets ... tabletop for precise positioning. ... allows for immediate and ... the C-Arm, making it ...
... The REFLEXION 1st MPJ IMPLANT SYSTEM is ... primary reconstruction of the 1st metatarsal phalangeal ... arthritis or revision of a previous arthroplasty. ... three goals: pain relief, superior function and ...
... hands play an important part in our ... and rheumatic changes can cause severe handicaps. ... the finger-joint prostheses was to produce a ... natural function as nearly possible.,The cementless RM ...
... The Low Profile Leg Holder provides precise control ... leg rotation, and maximum exposure of the proximal ... Profile Leg Holder can be used on both ... to different heights.,The Low Profile Leg Holder can ...
Medicine Products: